Attenuation and reversion of the Sabin vaccine strains of poliovirus
Minor, P.D.
Developments in Biological Standardization 78: 17-26
1993
ISSN/ISBN: 0301-5149 PMID: 8388828 Document Number: 411383
Studies of the molecular basis of the attenuation and reversion of the attenuated phenotype of the Sabin vaccine strains suggest that few mutations are involved. It is striking that mutations in the 5' non-coding region within a 10 base region implicated in a base pair structure have been identified in all the Sabin vaccine strains. The mutations have effects on in vitro phenotypes which have implications for the production of vaccines.
Document emailed within 1 workday
Related Documents
Friedrich, F.; Filippis, A.M.; Schatzmayr, H.G. 1996: Temporal association between the isolation of Sabin-related poliovirus vaccine strains and the Guillain-Barré syndrome Revista do Instituto de Medicina Tropical de Sao Paulo 38(1): 55-58Kado, G. 1976: Relative sensitivity of three cell substrates to the Sabin poliovirus strains Developments in Biological Standardization 37: 261-264
Friedrich, F. 2000: Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus Acta Virologica 44(2): 109-117
Iakovenko, M.L.; Korotkova, E.A. 2008: Evolution of vaccine poliovirus strains Voprosy Virusologii 53(3): 45-48 Following Back Cover
Nakano, J.H.; Hatch, M.H.; Thieme, M.L.; Nottay, B. 1978: Parameters for differentiating vaccine-derived and wild poliovirus strains Progress in Medical Virology. Fortschritte der Medizinischen Virusforschung. Progres en Virologie Medicale 24: 178-206
Almond, J.W.; Stone, D.; Burke, K.; Skinner, M.A.; Macadam, A.J.; Wood, D.; Ferguson, M.; Minor, P.D. 1993: Approaches to the construction of new candidate poliovirus type 3 vaccine strains Developments in Biological Standardization 78: 161-169; Discussion: 169-170
Shen, H.-H.; Hou, J.; Hu, Y.; Bai, B.-K.; Wang, Z.-J.; Yu, X.-H.; Kong, W.; Liu, Z.; Mao, P.-Y. 2010: Construction and identification of a vector inserted with complete genome of poliovirus strain Sabin i Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(1): 59-61
Dowdle, W.R.; Wolff, C.; Sanders, R.; Lambert, S.; Best, M. 2004: Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bulletin of the World Health Organization 82(1): 59-62
Chowdhary, R.; Dhole, T.N. 2008: Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India Journal of Medical Virology 80(8): 1477-1488
Kiseleva, I.V.; Klimov, A.I.; Grigor'eva, E.P.; Larionova, N.V.; Aleksandrova, G.I.; Rudenko, L.G. 2005: Genetic and phenotypic analysis of heterogeneous population of a cold-adapted donor of the A/Leningrad/134/17/57 (H2N2) attenuation and of the donor-based reassortant influenza vaccine strains Voprosy Virusologii 50(2): 14-18
John, T.J. 1993: Poliovirus neurovirulence and attenuation, a conceptual framework Developments in Biological Standardization 78: 117-119
Racaniello, V.R.; Ren, R.; Bouchard, M. 1993: Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis Developments in Biological Standardization 78: 109-116
Más Lago, P.; Díaz, J.; Díaz Gonzalez, M.; Goyenechea Hernández, A.; Barrio Olivera, J.; Fonseca Quintana, M.; Morier Díaz, L.; Sarmiento Pérez, L.; Palomera Puente, R. 2005: Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine Revista Cubana de Medicina Tropical 57(2): 111-119
Dong, D.X.; Hu, X.M.; Liu, W.J.; Li, J.S.; Jin, Y.C.; Tan, S.G.; Chen, T.Q.; Fu, J.Z.; Niu, B.Y.; Yu, H.M. 1986: Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin) Bulletin of the World Health Organization 64(6): 853-860
Troy, S.B.; Musingwini, G.; Halpern, M.S.; Huang, C.; Stranix-Chibanda, L.; Kouiavskaia, D.; Shetty, A.K.; Chumakov, K.; Nathoo, K.; Maldonado, Y.A. 2013: Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants Journal of Infectious Diseases 208(4): 672-678
Lin, T.-Y.; Wang, Y.-H.; Chang, L.-Y.; Chiu, C.-H.; Huang, Y.-C.; Tang, H.; Bock, H.L. 2003: Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age Chang Gung Medical Journal 26(5): 315-322
Hils, J.; Böthig, B. 1974: Adsorption and elution of poliovirus type 2 strains in Al (OH)3 gel Zeitschrift für die Gesamte Hygiene und ihre Grenzgebiete 20(8): 529-530
Dreazen, J.R. 1999: Cost of inactivated vs. oral poliovirus vaccine American Family Physician 60(7): 1929; 1932
Lecatsas, G.; Alexander, J.J. 1989: Safe testing of poliovirus vaccine and the origin of HIV in man South African Medical Journal 76(8): 451
Wieckiewicz, J. 1976: Changes in biochemical features and sensitivity to beta-lactam antibiotics and lysozyme in Staphylococcus aureus strains following reversion from the L-phase Medycyna Doswiadczalna i Mikrobiologia 28(4): 341-346